VinCaP

Collection of samples and data across the following diseases: Malignant tumour of penis (disorder) VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoints are objective response rate (CR+PR), toxicity, progression-free survival, overall survival and treatment compliance. Formalin fixed paraffin embedded (FFPE) tumour blocks are held at the Orchid Tissue Laboratory and Barts and The London School of Medicine and Dentistry.

Webpage:
https://www.healthdatagateway.org/dataset/5bb40472-fc5d-4b16-a0a6-d1d42fd1d3e8

Licence:
Name: HDR UK Innovation Gateway Access
URL: https://www.hdruk.ac.uk/infrastructure/gateway/terms-and-conditions/

Tags:

malignant tumour of penis (disorder) vincap

More to explore:

1/20

Previous Next   



Need help integrating and/or managing biomedical data?